
ATAI Stock Forecast & Price Target
ATAI Analyst Ratings
Bulls say
AtaiBeckley is a clinical-stage biopharmaceutical company with a promising pipeline of therapies for treating mental health disorders. The recent deal with Eli Lilly, with a total value of approximately $2.8 billion, further validates the potential of these therapies and highlights the attractiveness of the TRD market. With a lowered probability of success for BPL-003 and VLS-01 due to updated clinical data, AtaiBeckley's valuation and potential peak revenues have been revised, but the current premium of ~40% over the last one-month average price suggests the market has confidence in the company's future success.
Bears say
AtaiBeckley is currently experiencing upside risks due to potential acquisition interest in the company, a positive Phase 2b topline readout for VLS-01 triggering a milestone payment, and expedited FDA approval for their therapies. However, there are concerns about the sustainability of the company's treatment model in terms of providing adequate clinical depth and durability while still maintaining operational convenience and cost-effectiveness. Additionally, the potential for additional bidders to enter the market could drive up the acquisition price, making it an uncertain investment opportunity.
This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.
ATAI Analyst Forecast & Price Prediction
Start investing in ATAI
Order type
Buy in
Order amount
Est. shares
0 shares